Wed, Oct 22, 2014, 12:22 PM EDT - U.S. Markets close in 3 hrs 38 mins

Recent

% | $
Quotes you view appear here for quick access.

InspireMD, Inc. Message Board

  • rrtzrealmd rrtzrealmd Oct 18, 2013 10:48 AM Flag

    What a joke!

    ..."proprietary stent platform technology"????...HAW!!...rule number one: a company claims something is "proprietary" -- RUN AWAY!...

    ..."We believe that patients will benefit from a cost-effective alternative which we believe will prove to have a superior clinical efficacy and safety profile than other stent technologies."????...and I believe some day I'll see a pig flying through a snowstorm in Hades -- but I won't bet on it!...

    ...so what these clowns sell is a wire mesh that slides over the top of a stent and allegedly improves patient outcomes?...that's it?...a wire mesh?...NOTHING else?...

    ...hold on while I relieve myself --- HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW!!!...

    ...whew!...that's better!...

    ...and the thing's not even approved in the US or Japan????...but management "believes" they will get approval as a class III medical device?...these guys sure do "believe" a lot, don't they?...

    ...and how have sales been going?...5 million bucks in 2012...4 million bucks in 2013?....hmmmmmmm...??????...correct me if I'm wrong but shouldn't sales be going UP?...

    ...ignoring that and even ignoring the THIRTY MILLION dollars they LOST in 2013 as well as the SEVENTEEN MILLION they LOST in 2012, have they done any sort of market study to see how many they can expect to sell even if they do get US approval?...

    ...looks to me to be NOTHING more than a "story" that stockbrokers think they can sell to naive investors......

    ...

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Are you new to this whole biotech / medical device field? Are you not aware that drugs and medical devices need to be developed and then go through several stages of testing before they can be marketed and sold? And that it costs money to develop and test those products?

      Are you not aware that the company's "beliefs" (as any forward looking statement necessarily is) are supported by the results of their clinical tests? And that further results from these tests will be released later this month?

      If what you have here is your best argument for being short this stock, I would suggest you are about to lose a lot of money (how much depending on how soon you decide to capitulate and cover).

      • 1 Reply to sagamore11
      • ...uhhhhhh, yes, yes yes, yes and yes...I'm also aware that the ONLY thing the company makes is a wire "mesh" that slips over the stent before placement...and -- much more importantly -- despite being available in practically every country on earth EXCEPT the US, their international sales DECLINED the past two years...

        ...and that is DESPITE being eligible for insurance reimbursement in at least one large country -- i.e. Brazil...

        ...got all that?...D-E-C-L-I-N-E-D!...where I come from, when a device serves a useful purpose and is reasonably priced, sales go up, not DOWN...

        ...then, like I said, tack on the 21 and 17 MILLION dollar losses the past two years and the "who knows when" US approval...

        ...and don't ignore the paragraph in the annual report about all of those distributors "who did not adhere to its order minimum for 2012 and 2013"...I counted at least a half dozen of those...what's their problem other than no one wants to buy the thing?...

        ...not to mention that NSPR is (was?) an ISRAELI company -- excuse enough not to buy the stock...but what's that paragraph about "We may have violated Israeli securities law"?...say what:

        "To date, the Israel Securities Authority has not responded to InspireMD Ltd.’s application for no-action determination and we are unable to predict when a response will be received."

        ...well, that's nice...nothing more I'd want to do than sit around waiting for this little possibility:

        "...imprisonment of five years; a fine of up to approximately $317,000 to be paid by management of the violating company; and a fine of up to approximately $1,590,000 to be paid by the violating company, any of which penalties could result in a material adverse effect on our operations."

        ...yeah, I can see how sending management to jail for five years could be an "adverse effect"...HAW!

 
NSPR
1.81+0.02(+1.12%)11:49 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.